Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsEisuke MEKADA, Ryo IWAMOTO, Shingo MIYAMOTO, Kenya SHITARA, Akiko FURUYA, Kazuyasu NAKAMURA, Kumiko TAKAHASHI, Hiroshi ANDO, Kazuhiro MASUDA, Yuka SASAKI
Life of this patent
Estimating the term…
Abstract
Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
Claims14
1-17. (canceled)
An isolated antibody or fragment thereof, wherein said antibody or said fragment comprises at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region comprises the amino acid sequence of SEQ ID NO:22, and wherein said light chain variable region comprises the amino acid sequence of SEQ ID NO:43.
An isolated antibody or fragment thereof, wherein said antibody or said fragment comprises at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region comprises the amino acid sequence of SEQ ID NO:42, and wherein said light chain variable region comprises the amino acid sequence of SEQ ID NO:23.
An isolated antibody fragment thereof, wherein said antibody or said fragment comprises at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region, wherein said heavy chain variable region comprises the amino acid sequence of SEQ ID NO:42, and wherein said light chain variable region comprises the amino acid sequence of SEQ ID NO:43.
The antibody fragment according to any one of claims 18 to 20, 29 and 30, which is selected from Fab, Fab′, F(ab′)2, a single chain antibody (scFv), a dimerized V region (diabody), a disulfide stabilized V region (dsFv), and a peptide comprising six CDRs.
A DNA encoding the antibody or the antibody fragment thereof according to any one of claims 18 to 20, 29 and 30.
A process for producing the antibody or the antibody fragment thereof according to any one of claims 18 to 20, 29 and 30, which comprises culturing the transformant according to claim 24 in a medium to form and accumulate the antibody or the antibody fragment thereof according to any one of claims 18 to 20, 29 and 30 in the culture, and recovering the antibody or the antibody fragment from the culture.
A pharmaceutical composition comprising the antibody or the antibody fragment thereof according to any one of claims 18 to 20, 29 and 30 as active ingredient.
An agent for treating a disease relating to HB-EGF, comprising the antibody or the antibody fragment thereof according to any one of claims 18 to 20, 29 and 30 as an active ingredient.
An isolated antibody or fragment thereof, wherein said antibody or said fragment comprises at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region comprises three complementarity—determining regions comprising the amino acid sequences of SEQ ID NOS:12, 13 and 14;
- and wherein said light chain variable region comprises the amino acid sequence of SEQ ID NO:43.
An isolated antibody or fragment thereof, wherein said antibody or said fragment comprises at least one heavy chain variable region and at least one light chain variable region, wherein said heavy chain variable region comprises the amino acid sequence of SEQ ID NO:42;
- and wherein said light chain variable region comprises at least three complementarity-determining regions comprising the amino acid sequences of SEQ ID NOS:15, 16 and 17.
Dependencies are inferred from the claim text.